1. Anti-fibroblast growth factor-2 antibodies attenuate mechanical allodynia in a rat model of neuropathic pain.
- Author
-
Madiai F, Goettl VM, Hussain SR, Clairmont AR, Stephens RL Jr, and Hackshaw KV
- Subjects
- Animals, Antibodies administration & dosage, Astrocytes cytology, Fibroblast Growth Factor 2 genetics, Fibroblast Growth Factor 2 immunology, Glial Fibrillary Acidic Protein genetics, Glial Fibrillary Acidic Protein metabolism, Injections, Spinal, Male, Pain physiopathology, Pain Measurement, Peripheral Nerve Injuries, Rats, Rats, Sprague-Dawley, Spinal Cord cytology, Astrocytes metabolism, Fibroblast Growth Factor 2 metabolism, Hyperesthesia physiopathology, Neuralgia physiopathology
- Abstract
Peripheral nerve injury leads to the activation of spinal cord astrocytes, which contribute to maintaining neuropathic (NP) pain behavior. Fibroblast growth factor-2 (FGF-2), a neurotrophic and gliogenic factor, is upregulated by spinal cord astrocytes in response to ligation of spinal nerves L5 and L6 (spinal nerve ligation [SpNL]). To evaluate the contribution of spinal astroglial FGF-2 to mechanical allodynia following SpNL, neutralizing antibodies to FGF-2 were injected intrathecally. Administration of 18 microg of anti-FGF-2 antibodies attenuated mechanical allodynia at day 21 after SpNL and reduced FGF-2 and glial acidic fibrillary protein mRNA expression and immunoreactivity in the L5 spinal cord segment of rats with SpNL. These results suggest that endogenous astroglial FGF-2 contributes to maintaining NP tactile allodynia associated with reactivity of spinal cord astrocytes and that inhibition of spinal FGF-2 ameliorates NP pain signs.
- Published
- 2005
- Full Text
- View/download PDF